Loading…

Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine

Highlights • BDNF level is a potential biomarker toward response to antidepressants. • Major depressive disorder (MDD) was treated with fluoxetine or desvenlafaxine. • Randomized, open-label study assessed efficacy, safety and plasma BDNF levels. • Both medicines comparably improved HAM-D scores and...

Full description

Saved in:

Bibliographic Details
Published in:	Asian journal of psychiatry 2015-12, Vol.18, p.37-41
Main Authors:	Ghosh, R, Gupta, R, Bhatia, M.S, Tripathi, A.K, Gupta, L.K
Format:	Article
Language:	English
Subjects:	Adult Antidepressive Agents - administration & dosage Antidepressive Agents - adverse effects BDNF Brain-Derived Neurotrophic Factor - metabolism Depression Depressive Disorder, Major - diagnosis Depressive Disorder, Major - drug therapy Depressive Disorder, Major - metabolism Depressive Disorder, Major - psychology Desvenlafaxine Desvenlafaxine Succinate - administration & dosage Desvenlafaxine Succinate - adverse effects Diagnostic and Statistical Manual of Mental Disorders Drug Monitoring - methods Female Fluoxetine Fluoxetine - administration & dosage Fluoxetine - adverse effects Humans Internal Medicine Male MDD Middle Aged Open label Prognosis Psychiatric Status Rating Scales Psychiatry Treatment Outcome
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c478t-15cb352a8bb75929445aafa570516bced099ab6407f7b91b58af2130c3f4e8d73
cites	cdi_FETCH-LOGICAL-c478t-15cb352a8bb75929445aafa570516bced099ab6407f7b91b58af2130c3f4e8d73
container_end_page	41
container_issue
container_start_page	37
container_title	Asian journal of psychiatry
container_volume	18
creator	Ghosh, R Gupta, R Bhatia, M.S Tripathi, A.K Gupta, L.K
description	Highlights • BDNF level is a potential biomarker toward response to antidepressants. • Major depressive disorder (MDD) was treated with fluoxetine or desvenlafaxine. • Randomized, open-label study assessed efficacy, safety and plasma BDNF levels. • Both medicines comparably improved HAM-D scores and tolerated well in depression. • Both the antidepressant agents significantly increased BDNF levels.
doi_str_mv	10.1016/j.ajp.2015.10.006
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751488869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1876201815002324</els_id><sourcerecordid>1751488869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-15cb352a8bb75929445aafa570516bced099ab6407f7b91b58af2130c3f4e8d73</originalsourceid><addsrcrecordid>eNp9ksFu1DAQhiMEoqXwAFyQj0XqLnbixI6QkGChgFTBAThbjj1WHZI42M7SfSJekwlbeuDAyfbon2-s_5-ieMrollHWvOi3up-3JWU1vreUNveKUyZFsylp2dy_uzN5UjxKqUeBrLh4WJyUTc045-K0-LUL46yjT2EiwRFwzhttDhckaQf5QPRkSRe1n4iF6PdgyQRLDDmG-dob4rTJIZLzN28_XT4nA-xhSATFs84eppxW5qh7lFiYI6SECGJxWkTcBckRdEbmT5-viRuWcAPZT_BnqoW0h2nQTt9g6XHxwOkhwZPb86z4dvnu6-7D5urz-4-711cbw4XMG1abrqpLLbtO1G3Zcl5rJNSC1qzpDFjatrprOBVOdC3raqldySpqKsdBWlGdFedH7hzDjwVSVqNPBoZBTxCWpJhA56SUTYtSdpSaGFKK4NQc_ajjQTGq1nxUrzAfteazltB-7Hl2i1-6Eexdx99AUPDyKEAjYe8hqmTQSfy5j2CyssH_F__qn24z-AkTHb7DAVIfljihe4qpVCqqvqwLsu4Hqyktq5JXvwHmk7iA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1751488869</pqid></control><display><type>article</type><title>Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine</title><source>Elsevier</source><creator>Ghosh, R ; Gupta, R ; Bhatia, M.S ; Tripathi, A.K ; Gupta, L.K</creator><creatorcontrib>Ghosh, R ; Gupta, R ; Bhatia, M.S ; Tripathi, A.K ; Gupta, L.K</creatorcontrib><description>Highlights • BDNF level is a potential biomarker toward response to antidepressants. • Major depressive disorder (MDD) was treated with fluoxetine or desvenlafaxine. • Randomized, open-label study assessed efficacy, safety and plasma BDNF levels. • Both medicines comparably improved HAM-D scores and tolerated well in depression. • Both the antidepressant agents significantly increased BDNF levels.</description><identifier>ISSN: 1876-2018</identifier><identifier>EISSN: 1876-2026</identifier><identifier>DOI: 10.1016/j.ajp.2015.10.006</identifier><identifier>PMID: 26514447</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Antidepressive Agents - administration & dosage ; Antidepressive Agents - adverse effects ; BDNF ; Brain-Derived Neurotrophic Factor - metabolism ; Depression ; Depressive Disorder, Major - diagnosis ; Depressive Disorder, Major - drug therapy ; Depressive Disorder, Major - metabolism ; Depressive Disorder, Major - psychology ; Desvenlafaxine ; Desvenlafaxine Succinate - administration & dosage ; Desvenlafaxine Succinate - adverse effects ; Diagnostic and Statistical Manual of Mental Disorders ; Drug Monitoring - methods ; Female ; Fluoxetine ; Fluoxetine - administration & dosage ; Fluoxetine - adverse effects ; Humans ; Internal Medicine ; Male ; MDD ; Middle Aged ; Open label ; Prognosis ; Psychiatric Status Rating Scales ; Psychiatry ; Treatment Outcome</subject><ispartof>Asian journal of psychiatry, 2015-12, Vol.18, p.37-41</ispartof><rights>Elsevier B.V.</rights><rights>2015 Elsevier B.V.</rights><rights>Copyright © 2015 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-15cb352a8bb75929445aafa570516bced099ab6407f7b91b58af2130c3f4e8d73</citedby><cites>FETCH-LOGICAL-c478t-15cb352a8bb75929445aafa570516bced099ab6407f7b91b58af2130c3f4e8d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26514447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghosh, R</creatorcontrib><creatorcontrib>Gupta, R</creatorcontrib><creatorcontrib>Bhatia, M.S</creatorcontrib><creatorcontrib>Tripathi, A.K</creatorcontrib><creatorcontrib>Gupta, L.K</creatorcontrib><title>Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine</title><title>Asian journal of psychiatry</title><addtitle>Asian J Psychiatr</addtitle><description>Highlights • BDNF level is a potential biomarker toward response to antidepressants. • Major depressive disorder (MDD) was treated with fluoxetine or desvenlafaxine. • Randomized, open-label study assessed efficacy, safety and plasma BDNF levels. • Both medicines comparably improved HAM-D scores and tolerated well in depression. • Both the antidepressant agents significantly increased BDNF levels.</description><subject>Adult</subject><subject>Antidepressive Agents - administration & dosage</subject><subject>Antidepressive Agents - adverse effects</subject><subject>BDNF</subject><subject>Brain-Derived Neurotrophic Factor - metabolism</subject><subject>Depression</subject><subject>Depressive Disorder, Major - diagnosis</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Depressive Disorder, Major - metabolism</subject><subject>Depressive Disorder, Major - psychology</subject><subject>Desvenlafaxine</subject><subject>Desvenlafaxine Succinate - administration & dosage</subject><subject>Desvenlafaxine Succinate - adverse effects</subject><subject>Diagnostic and Statistical Manual of Mental Disorders</subject><subject>Drug Monitoring - methods</subject><subject>Female</subject><subject>Fluoxetine</subject><subject>Fluoxetine - administration & dosage</subject><subject>Fluoxetine - adverse effects</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>MDD</subject><subject>Middle Aged</subject><subject>Open label</subject><subject>Prognosis</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Treatment Outcome</subject><issn>1876-2018</issn><issn>1876-2026</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9ksFu1DAQhiMEoqXwAFyQj0XqLnbixI6QkGChgFTBAThbjj1WHZI42M7SfSJekwlbeuDAyfbon2-s_5-ieMrollHWvOi3up-3JWU1vreUNveKUyZFsylp2dy_uzN5UjxKqUeBrLh4WJyUTc045-K0-LUL46yjT2EiwRFwzhttDhckaQf5QPRkSRe1n4iF6PdgyQRLDDmG-dob4rTJIZLzN28_XT4nA-xhSATFs84eppxW5qh7lFiYI6SECGJxWkTcBckRdEbmT5-viRuWcAPZT_BnqoW0h2nQTt9g6XHxwOkhwZPb86z4dvnu6-7D5urz-4-711cbw4XMG1abrqpLLbtO1G3Zcl5rJNSC1qzpDFjatrprOBVOdC3raqldySpqKsdBWlGdFedH7hzDjwVSVqNPBoZBTxCWpJhA56SUTYtSdpSaGFKK4NQc_ajjQTGq1nxUrzAfteazltB-7Hl2i1-6Eexdx99AUPDyKEAjYe8hqmTQSfy5j2CyssH_F__qn24z-AkTHb7DAVIfljihe4qpVCqqvqwLsu4Hqyktq5JXvwHmk7iA</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Ghosh, R</creator><creator>Gupta, R</creator><creator>Bhatia, M.S</creator><creator>Tripathi, A.K</creator><creator>Gupta, L.K</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151201</creationdate><title>Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine</title><author>Ghosh, R ; Gupta, R ; Bhatia, M.S ; Tripathi, A.K ; Gupta, L.K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-15cb352a8bb75929445aafa570516bced099ab6407f7b91b58af2130c3f4e8d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Antidepressive Agents - administration & dosage</topic><topic>Antidepressive Agents - adverse effects</topic><topic>BDNF</topic><topic>Brain-Derived Neurotrophic Factor - metabolism</topic><topic>Depression</topic><topic>Depressive Disorder, Major - diagnosis</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Depressive Disorder, Major - metabolism</topic><topic>Depressive Disorder, Major - psychology</topic><topic>Desvenlafaxine</topic><topic>Desvenlafaxine Succinate - administration & dosage</topic><topic>Desvenlafaxine Succinate - adverse effects</topic><topic>Diagnostic and Statistical Manual of Mental Disorders</topic><topic>Drug Monitoring - methods</topic><topic>Female</topic><topic>Fluoxetine</topic><topic>Fluoxetine - administration & dosage</topic><topic>Fluoxetine - adverse effects</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>MDD</topic><topic>Middle Aged</topic><topic>Open label</topic><topic>Prognosis</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghosh, R</creatorcontrib><creatorcontrib>Gupta, R</creatorcontrib><creatorcontrib>Bhatia, M.S</creatorcontrib><creatorcontrib>Tripathi, A.K</creatorcontrib><creatorcontrib>Gupta, L.K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Asian journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghosh, R</au><au>Gupta, R</au><au>Bhatia, M.S</au><au>Tripathi, A.K</au><au>Gupta, L.K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine</atitle><jtitle>Asian journal of psychiatry</jtitle><addtitle>Asian J Psychiatr</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>18</volume><spage>37</spage><epage>41</epage><pages>37-41</pages><issn>1876-2018</issn><eissn>1876-2026</eissn><abstract>Highlights • BDNF level is a potential biomarker toward response to antidepressants. • Major depressive disorder (MDD) was treated with fluoxetine or desvenlafaxine. • Randomized, open-label study assessed efficacy, safety and plasma BDNF levels. • Both medicines comparably improved HAM-D scores and tolerated well in depression. • Both the antidepressant agents significantly increased BDNF levels.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26514447</pmid><doi>10.1016/j.ajp.2015.10.006</doi><tpages>5</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 1876-2018
ispartof	Asian journal of psychiatry, 2015-12, Vol.18, p.37-41
issn	1876-2018 1876-2026
language	eng
recordid	cdi_proquest_miscellaneous_1751488869
source	Elsevier
subjects	Adult Antidepressive Agents - administration & dosage Antidepressive Agents - adverse effects BDNF Brain-Derived Neurotrophic Factor - metabolism Depression Depressive Disorder, Major - diagnosis Depressive Disorder, Major - drug therapy Depressive Disorder, Major - metabolism Depressive Disorder, Major - psychology Desvenlafaxine Desvenlafaxine Succinate - administration & dosage Desvenlafaxine Succinate - adverse effects Diagnostic and Statistical Manual of Mental Disorders Drug Monitoring - methods Female Fluoxetine Fluoxetine - administration & dosage Fluoxetine - adverse effects Humans Internal Medicine Male MDD Middle Aged Open label Prognosis Psychiatric Status Rating Scales Psychiatry Treatment Outcome
title	Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A07%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20efficacy,%20safety%20and%20brain%20derived%20neurotrophic%20factor%20(BDNF)%20levels%20in%20patients%20of%20major%20depressive%20disorder,%20treated%20with%20fluoxetine%20and%20desvenlafaxine&rft.jtitle=Asian%20journal%20of%20psychiatry&rft.au=Ghosh,%20R&rft.date=2015-12-01&rft.volume=18&rft.spage=37&rft.epage=41&rft.pages=37-41&rft.issn=1876-2018&rft.eissn=1876-2026&rft_id=info:doi/10.1016/j.ajp.2015.10.006&rft_dat=%3Cproquest_cross%3E1751488869%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-15cb352a8bb75929445aafa570516bced099ab6407f7b91b58af2130c3f4e8d73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1751488869&rft_id=info:pmid/26514447&rfr_iscdi=true